Stratos Wealth Partners LTD. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the third quarter, HoldingsChannel.com reports. The fund owned 144,700 shares of the company’s stock after acquiring an additional 1,600 shares during the quarter. Johnson & Johnson accounts for approximately 0.7% of Stratos Wealth Partners LTD.’s portfolio, making the stock its 20th largest position. Stratos Wealth Partners LTD.’s holdings in Johnson & Johnson were worth $21,543,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. 55I LLC lifted its stake in Johnson & Johnson by 87.8% in the third quarter. 55I LLC now owns 6,681 shares of the company’s stock worth $995,000 after purchasing an additional 3,124 shares during the last quarter. Capital Investment Advisors LLC lifted its stake in Johnson & Johnson by 2.3% in the third quarter. Capital Investment Advisors LLC now owns 250,037 shares of the company’s stock worth $37,225,000 after purchasing an additional 5,659 shares during the last quarter. IFP Advisors Inc lifted its stake in Johnson & Johnson by 7.7% in the third quarter. IFP Advisors Inc now owns 53,544 shares of the company’s stock worth $7,949,000 after purchasing an additional 3,832 shares during the last quarter. Greenwich Wealth Management LLC lifted its stake in Johnson & Johnson by 9.6% in the third quarter. Greenwich Wealth Management LLC now owns 2,589 shares of the company’s stock worth $385,000 after purchasing an additional 226 shares during the last quarter. Finally, Parsons Capital Management Inc. RI lifted its stake in Johnson & Johnson by 0.6% in the third quarter. Parsons Capital Management Inc. RI now owns 118,631 shares of the company’s stock worth $17,662,000 after purchasing an additional 733 shares during the last quarter. 67.44% of the stock is owned by institutional investors.
Several brokerages have recently commented on JNJ. Raymond James upped their price objective on shares of Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the company from $161.00 to $164.00 in a research note on Monday, July 20th. Cantor Fitzgerald upped their price objective on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, SVB Leerink reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $164.93.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.27% of the company’s stock.
Shares of JNJ opened at $142.25 on Friday. The stock has a market cap of $374.48 billion, a PE ratio of 22.37, a price-to-earnings-growth ratio of 2.99 and a beta of 0.69. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The firm’s 50-day simple moving average is $145.34 and its two-hundred day simple moving average is $146.91.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s revenue was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.12 earnings per share. Equities research analysts predict that Johnson & Johnson will post 7.99 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.01 dividend. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $4.04 annualized dividend and a dividend yield of 2.84%. Johnson & Johnson’s dividend payout ratio is presently 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: What does a dividend yield signify to investors?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.